IDT Australia Limited (IDT) AI Stock Analysis

• Market Cap: AU$17.27M
• Dividend Yield: N/A
• Average Volume (3M): 336.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.20
• Revenue Growth: 45.30%
• EPS Growth: -24.18%
• Country: AU
• Employees: 156
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 427,425,570
• 10 Day Avg. Volume: 373,970
• 30 Day Avg. Volume: 336,941
• PEG Ratio: -0.21
• Price to Book (P/B): 1.73
• Price to Sales (P/S): 1.92
• P/FCF Ratio: -5.03
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: AU$0.04 ▼(-18.00% Downside)
• Action: Reiterated Date: 02/19/26
• Date: Action: Reiterated 02/19/26

The score is primarily held back by weak financial performance, including ongoing losses and negative operating/free cash flow. Technical signals are mixed with neutral momentum but a weaker longer-term trend, while valuation is also pressured due to loss-making earnings and no dividend support.

Positive Factors

CDMO fee-for-service model

IDT's fee-for-service CDMO model produces diversified, contract-driven revenue across manufacturing, development and logistics. Structural pharma outsourcing supports repeatable, utilization-linked revenues and long-term customer relationships, offering durable revenue visibility if facilities stay compliant.

Consistent modest revenue growth

Modest but consistent top-line growth indicates the business can win and expand contracts. Over a multi-month horizon steady revenue supports potential operating leverage as utilization rises and fixed costs are absorbed, improving prospects for margin recovery if cost discipline continues.

Stable equity ratio / asset base

A stable equity ratio points to a solid asset base that can support operations and capital investment. This balance-sheet stability provides resilience through operational cycles, aids regulatory compliance investments, and improves access to external financing when growth or capex is required.

Negative Factors

Negative operating and free cash flow

Persistent negative operating and free cash flow constrains IDT's ability to internally fund capex, working capital and regulatory investments. Over months this forces reliance on external financing, increasing dilution or interest burden and limiting capacity expansion to capture new contracts.

Ongoing losses and weak margins

Negative net profit and EBIT margins with declining gross margin indicate structural cost or pricing pressure. Continued losses reduce reinvestment ability, impair return on capital and make it harder to compete for higher-margin CDMO work, threatening long-term profitability without margin recovery.

Rising leverage

An increasing debt-to-equity ratio raises financial risk by adding fixed obligations. Coupled with negative cash flow and losses, higher leverage reduces flexibility to fund operations or capex, increases refinancing risk, and constrains strategic investment in capacity or compliance over the medium term.

IDT Australia Limited Business Overview & Revenue Model

Company Description

IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) and finished dose form products in Australia and internationally. It offers analytical method development, stability chambers, and chemistry and microbiology quality control laboratory services. The company also provides project management, chemical, analytical chemistry, pharmacy, clinical packaging, and regulatory affairs, as well as pharmaceutical development services in various dosage forms. In addition, it offers medicinal cannabis products, as well as various contract manufacturing services. The company was founded in 1975 and is headquartered in Boronia, Australia.

How the Company Makes Money

IDT primarily makes money by providing fee-for-service pharmaceutical contract development and manufacturing (CDMO) work. Key revenue streams include: (1) manufacturing services, where customers pay IDT to produce drug products (including sterile and non-sterile medicines) under contract; (2) development and technical services, where customers pay for formulation/development support, process development/scale-up, analytical and quality-related services associated with getting products ready for commercial manufacture; and (3) ancillary supply-chain services, where customers pay for activities such as packaging, release-related support, warehousing, and distribution/logistics. IDT’s earnings are driven by utilization of its manufacturing capacity, the volume and complexity of customer projects, and long-term supply/manufacturing agreements with pharmaceutical companies and other healthcare product sponsors. null

IDT Australia Limited Financial Statement Overview

Summary

Despite modest revenue growth (+5.28%), profitability and liquidity are weak: negative net profit and EBIT margins, declining gross margin, and concerning negative operating and free cash flows. Leverage has increased and ROE is negative, partially offset by a stable equity ratio.

Income Statement

IDT Australia Limited has shown some revenue growth, with a 5.28% increase in the latest year. However, the company is struggling with profitability, as indicated by negative net profit margins and EBIT margins. The gross profit margin has also declined compared to previous years, suggesting challenges in cost management or pricing power.

Balance Sheet

The company's debt-to-equity ratio has increased, indicating higher leverage, but it remains relatively low compared to industry standards. The return on equity is negative, reflecting ongoing losses. However, the equity ratio is stable, suggesting a solid asset base relative to equity.

Cash Flow

IDT Australia Limited's cash flow situation is concerning, with negative operating and free cash flows. The free cash flow growth rate is negative, and the operating cash flow to net income ratio indicates inefficiencies in converting income into cash. This poses liquidity risks.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	19.00M	19.77M	13.23M	6.93M	12.11M	15.99M
Gross Profit	7.10M	9.69M	10.42M	-3.53M	2.82M	4.88M
EBITDA	-4.11M	-6.54M	-5.56M	-8.83M	-340.00K	2.75M
Net Income	-6.13M	-8.06M	-5.41M	-8.50M	-1.16M	2.10M
Balance Sheet
Total Assets	34.55M	36.92M	31.37M	28.29M	30.08M	34.13M
Cash, Cash Equivalents and Short-Term Investments	1.93M	4.11M	904.00K	4.43M	9.21M	6.93M
Total Debt	9.86M	10.40M	4.47M	740.00K	881.00K	766.00K
Total Liabilities	14.23M	15.03M	7.93M	4.15M	3.46M	6.51M
Stockholders Equity	20.31M	21.89M	23.44M	24.14M	26.63M	27.61M
Cash Flow
Free Cash Flow	-885.00K	-7.55M	-10.30M	-8.42M	1.95M	-156.00K
Operating Cash Flow	609.00K	-6.25M	-9.60M	-7.90M	2.86M	370.00K
Investing Cash Flow	-3.19M	-4.50M	-1.09M	-522.00K	-912.00K	-526.00K
Financing Cash Flow	3.46M	10.75M	6.77M	3.64M	337.00K	224.00K

IDT Australia Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDT, the sentiment is Negative. The current price of 0.05 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.05, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 28.80 is Positive, neither overbought nor oversold. The STOCH value of -28.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IDT.

IDT Australia Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIT	57 Neutral	AU$26.51M	-12.06	7.64%	3.28%	0.13%	-12.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MVP	46 Neutral	AU$44.50M	-69.17	-0.79%	―	17.82%	―
IDT	45 Neutral	AU$17.27M	-4.15	-29.05%	―	45.30%	-24.18%

IDT Australia Limited Corporate Events

IDT Australia Director Increases Indirect Shareholding via On-Market Purchase

IDT Australia has disclosed a change in director Mark Simari’s interests, with an indirect on-market purchase of 501,936 ordinary fully paid shares at $0.048 per share. The transaction, executed via entities Charkaroo Pty Ltd and Jodmar Pty Ltd, lifts his indirect holding to 1,087,912 shares while maintaining 6,000,000 unlisted options and was carried out during a closed period under prior written clearance, signaling increased director alignment with shareholders.

The notified acquisition underscores board-level confidence in the company’s prospects, as a director increases his exposure to equity rather than reducing it. For investors and other stakeholders, such a move can be interpreted as a positive governance signal, though it does not in itself alter the company’s operations, strategy, or capital structure beyond the incremental change in market ownership.

The most recent analyst rating on (AU:IDT) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on IDT Australia Limited stock, see the AU:IDT Stock Forecast page.

IDT Australia Cancels 164,000 Shares After Conditional Rights Lapse

IDT Australia Limited has announced the cessation of 164,000 ordinary fully paid shares following the lapse of conditional rights to these securities, after the specified conditions were not met or became incapable of being satisfied as of 29 September 2025. The reduction in potential issued capital reflects the non-vesting of these conditional rights, which may marginally affect future dilution expectations for existing shareholders but does not alter the company’s current issued share capital structure.

The most recent analyst rating on (AU:IDT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on IDT Australia Limited stock, see the AU:IDT Stock Forecast page.